[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627454":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":69,"collaborators":25,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":25,"eligibilityCriteria":77,"healthyVolunteers":74,"sex":78,"minAge":79,"maxAge":25,"enrollmentInfo":80,"targetDuration":25,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":96,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Riphah International University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intralesional Acyclovir","EXPERIMENTAL","Participants receive intralesional injection of acyclovir. Injections are administered at baseline and repeated every 2 weeks for a maximum of four sessions.",[13],"Drug: Intralesional Acyclovir",{"label":15,"type":16,"description":17,"interventionNames":18},"Intralesional Vitamin D3","ACTIVE_COMPARATOR","Participants receive intralesional injection of vitamin D3 (200,000 IU). Injections are administered at baseline and repeated every 2 weeks for a maximum of four sessions.",[19],"Drug: Intralesional Vitamin D3",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Acyclovir (70 mg\u002FmL) prepared by reconstituting a 250 mg vial with 3.5 mL of distilled water, injected directly into the wart lesion. Dosing is based on lesion size: 0.2 mL for warts ≤0.5 cm, 0.3-0.5 mL for 0.5-1 cm, and 0.5-1 mL for 1-1.5 cm. Administered at baseline and every 2 weeks for up to four sessions.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Vitamin D3 (200,000 IU; 5 mg\u002FmL) injected directly into the wart lesion. Dosing is based on lesion size: 0.2 mL for warts ≤0.5 cm, 0.3-0.5 mL for 0.5-1 cm, and 0.5-1 mL for 1-1.5 cm. Administered at baseline and every 2 weeks for up to four sessions.",[15],[30,53],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Railway General Hospital, Railway Carriage Factory Rd, Railway Scheme 7, Rawalpindi","RECRUITING","Rawalpindi","Punjab Province","46000","Pakistan","PK",{"type":39,"coordinates":40},"Point",[41,42],73.0479,33.59733,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Dr. Nadia Ghazanfar, MBBS, FCPS (Derm)","CONTACT","+92 312 5328994","nadia.ghazanfar@riphah.edu.pk",{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Nadia Ghazanfar, MBBS, FCPS (Derm)","PRINCIPAL_INVESTIGATOR",{"facility":54,"status":32,"city":55,"state":25,"zip":56,"country":36,"countryCode":37,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Riphah International Hospital, Islamabad Expy, Sector A DHA Phase 5, Islamabad","Islamabad","44000",{"type":39,"coordinates":58},[59,60],73.04329,33.72148,{"lat":60,"lon":59},[63,67],{"name":64,"role":47,"phone":65,"phoneExt":25,"email":66},"Dr. Fatima Sajid, MBBS, FCPS (Derm)","+92 334 435 2228","fatima.sajid@riphah.edu.pk",{"name":68,"role":52,"phone":25,"phoneExt":25,"email":25},"Fatima Sajid, MBBS, FCPS (Derm)",{"type":52,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Fatima Sajid","Principal Investigator","100627454","phase-4-intralesional-therapies-for-cutaneous-viral-warts-a-comparative-analysis-of-vitamin-d3-and-acyclovir-100627454",false,"NCT07448844","Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir","Inclusion Criteria:\n\n* Patients aged 12 years and above with clinically diagnosed cutaneous warts\n* Common, plantar, flat, or periungual warts\n* Both treatment-naïve patients and those with recalcitrant warts\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Immunocompromised patients\n* Individuals with history of hypersensitivity to vitamin D3 or acyclovir\n* Individuals receiving systemic immunosuppressive or antiviral therapy\n* Patients with secondary infection at injection site\n* Patients who had received any topical or destructive treatment for wart in previous three months","ALL","12 Years",{"count":81,"type":82},40,"ESTIMATED","INTERVENTIONAL",[85],"PHASE4","The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are:\n\n1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8?\n2. Which treatment clears warts more effectively?\n3. What side effects do participants have with each treatment?\n\nResearchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts.\n\nParticipants will:\n\n1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions\n2. Have photographs taken of their warts before treatment and at each visit\n3. Visit the clinic for checkups where the size and number of warts will be measured\n4. Be followed for up to 3 months to check for wart recurrence and side effects",[88,89,90,91,92,93,94,95],"Viral Wart","Plantar Wart","Common Warts (Verruca Vulgaris)","Common Wart","Flat Wart","Warts of Foot","Warts Hand","Wart",[97,98,99,100,101,102,103,104,105,106],"Cutaneous warts","intralesional therapy","treatment efficacy","plantar warts","common warts","human papillomavirus","randomized controlled trial","vitamin D3","acyclovir","flat warts","2026-03-06",{"date":109,"type":110},"2026-03-10","ACTUAL",{"date":112,"type":110},"2026-02-20",{"date":114,"type":82},"2026-05-20",{"name":5,"class":6},2]